Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s495659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Lin Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hebei North University, Zhangjiakou, Hebei, People's Republic of China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Diet, High-Fat, Glucagon-Like Peptides, Oxidative Stress. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hebei North University, Zhangjiakou, Hebei, People's Republic of China.
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
- Department of Internal Medicine, Shandong Medical College, Linyi, Shandong, People's Republic of China.
- Department of Endocrinology, The Second Hospital of Shijiazhuang, Shijiazhuang, Hebei, People's Republic of China.
- Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
- Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
Zitieren
APA
Yang, L., Pan, X., Pan, Z., Gao, H., Ban, J., & Chen, S. (2024). Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s495659
Vancouver
Yang L, Pan X, Pan Z, Gao H, Ban J, Chen S. Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s495659
BibTeX
@article{Yang2024,
author = {Yang, Lin and Pan, Xiaoyu and Pan, Zhenyu and Gao, Haina and Ban, Jiangli and Chen, Shuchun},
title = {Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s495659}
}
EUVIMED